Eli Lilly and Company (NYSE:LLY) Stock Price Down 0%

Eli Lilly and Company (NYSE:LLY) dropped 0% on Wednesday . The stock traded as low as $767.38 and last traded at $774.61. Approximately 685,312 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 3,209,096 shares. The stock had previously closed at $774.90.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LLY. Morgan Stanley raised their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Truist Financial restated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $689.52.

Eli Lilly and Company Stock Down 0.0 %

The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a market cap of $739.19 billion, a P/E ratio of 134.13, a price-to-earnings-growth ratio of 1.71 and a beta of 0.34. The company has a fifty day moving average of $730.97 and a 200 day moving average of $637.01.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.09 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 195,055 shares of company stock worth $125,254,657. Corporate insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Simon Quick Advisors LLC lifted its holdings in Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after buying an additional 278 shares during the period. Liontrust Investment Partners LLP purchased a new stake in Eli Lilly and Company during the third quarter worth $8,326,000. WASHINGTON TRUST Co lifted its holdings in shares of Eli Lilly and Company by 16.5% during the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after purchasing an additional 2,671 shares during the last quarter. Armstrong Fleming & Moore Inc purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $357,000. Finally, Redhawk Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock valued at $3,752,000 after purchasing an additional 65 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.